Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484744 | 0.88 | SIGMAR1 (0.52) | JAK1SIGMAR1TMEM97 | |
| SCHEMBL3121018 | 0.85 | UBE2M (0.60) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 | |
| SCHEMBL3118452 | 0.85 | UBE2M (0.60) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 | |
| SCHEMBL2221234 | 0.85 | UBE2M (0.60) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 | |
| SCHEMBL3121007 | 0.85 | UBE2M (0.60) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 | |
| SCHEMBL2221237 | 0.85 | UBE2M (0.60) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 | |
| SCHEMBL17185074 | 0.83 | KMT2A (0.53) | JAK1SIGMAR1DRD4DRD2L3MBTL1 | |
| SCHEMBL22233551 | 0.83 | SIGMAR1 (0.51) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 | |
| SCHEMBL22233549 | 0.83 | SIGMAR1 (0.51) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 | |
| SCHEMBL22233550 | 0.83 | SIGMAR1 (0.51) | SIGMAR1DRD4DRD2SCN4AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895550-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140045835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20110144100-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | JAK1 77/4885SIGMAR1 2000/4885DRD4 2771/4885 |
| US-20110144100-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM3, PIM2 | JAK1 17/4885SIGMAR1 746/4885DRD4 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.